CD79A and infection: With regard to novel agents (BTKi, BCL2i, PI3Ki) only ibrutinib has shown a potential impact on humoral reconstitution (mainly IgA) that lowered infection rate at 12 months from therapy start in a multicentered study (89), while data on humoral reconstitution during idelalisb or venetoclax are scarce and not encouraging (90).